Table 1 Baseline characteristics of all included 483 patients with advanced pancreatic cancer
From: Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study
Characteristics | BMI < 18.5 | BMI 18.5 - 25 | BMI 25 - 30 | BMI > =30 | Total |
|---|---|---|---|---|---|
N = 44 | N = 294 | N = 113 | N = 32 | N = 483 | |
Age at diagnosis | |||||
Median(IQR) | 64.3 (55.4, 73.6) | 67.1 (58.9, 74.2) | 66.6 (58.8, 74.1) | 63.7 (58.2, 67.2) | 66.4 (58.6, 74) |
Sex | |||||
Female | 24 (54.5) | 135 (45.9) | 36 (31.9) | 13 (40.6) | 208 (43.1) |
Male | 20 (45.5) | 159 (54.1) | 77 (68.1) | 19 (59.4) | 275 (56.9) |
ECOG at diagnosis | |||||
ECOG > =2 | 9 (20.5) | 64 (21.8) | 27 (23.9) | 5 (15.6) | 105 (21.7) |
ECOG < 2 | 35 (79.5) | 230 (78.2) | 86 (76.1) | 27 (84.4) | 378 (78.3) |
Stage at diagnosis | |||||
III | 8 (18.2) | 58 (19.7) | 22 (19.5) | 3 (9.4) | 91 (18.8) |
IV | 36 (81.8) | 236 (80.3) | 91 (80.5) | 29 (90.6) | 392 (81.2) |
CA19-9 at diagnosis | |||||
Median (IQR) | 392.1 (53.2, 2589.8) | 546.1 (66.5, 3644) | 801 (134.7, 4390) | 689 (207.7, 14630.7) | 609.6 (84.4, 3819.8) |
Diabetes at diagnosis | |||||
Diabetes | 10 (22.7) | 74 (25.2) | 29 (25.7) | 14 (43.8) | 127 (26.3) |
No-diabetes | 34 (77.3) | 220 (74.8) | 84 (74.3) | 18 (56.2) | 356 (73.7) |
RTX at any therapy line | |||||
No-RTX | 43 (97.7) | 273 (92.9) | 108 (95.6) | 30 (93.8) | 454 (94) |
RTX | 1 (2.3) | 21 (7.1) | 5 (4.4) | 2 (6.2) | 29 (6) |
Most frequent 1st line chemotherapies | |||||
Gem | 28 (63.6) | 173 (58.5) | 68 (60.2) | 17 (53.1) | 286 (59.2) |
Gem + Cap | 6 (13.6) | 39 (13.3) | 14 (12.4) | 6 (18.8) | 65 (13.5) |
Gem + Cis | 1 (2.3) | 14 (4.8) | 7 (6.2) | 0 (0) | 22 (4.6) |
BSC | 6 (13.6) | 23 (7.8) | 10 (8.8) | 2 (6.2) | 41 (8.5) |